TY - JOUR
T1 - Prognostic and predictive factors for anti-androgen withdrawal in castration-resistant prostate cancer
AU - Murakami, Tomohiko
AU - Obata, Hirofumi
AU - Akitake, Naoko
AU - Shiot, Masaki
AU - takeuchi, ario
AU - Kashiwagi, Eiji
AU - Inokuchi, Junichi
AU - Tatsugami, Katsunori
AU - Eto, Masatoshi
N1 - Funding Information:
This work was supported by JSPS KAKENHI Grant (17K11145), Research Promotion Grant from the Takeda Science Foundation, and Research Promotion Grant from the Shin-Nihon Advanced Medical Research Foundation. The Authors would also like to thank Edanz Group Japan for editorial assistance.
Publisher Copyright:
© 2018 International Institute of Anticancer Research. All rights reserved.
PY - 2018/7
Y1 - 2018/7
N2 - Background/Aim: We aimed to identify prognostic and predictive factors for anti-androgen withdrawal syndrome (AWS) to help guide decisions on anti-androgen withdrawal in castration-resistant prostate cancer (CRPC). Patients and Methods: This study included 95 patients with prostate cancer which progressed to CRPC despite primary androgen-deprivation therapy (ADT). AWS was defined as >50% prostate-specific antigen decline after anti-androgen withdrawal. Associations between AWS, and clinicopathological factors and prognosis were investigated. Results: Among the 95 patients, 84 (88.4%) underwent anti-androgen withdrawal, among whom AWS was recognized in nine (10.8%). Gleason score and response duration to primary ADT were predictors of AWS. Long duration of response to primary ADT was also associated with better progression-free survival [hazard ratio (HR)=0.021, 95% confidence interval (CI)=0.0025-0.14, p<0.0001] and overall survival (HR=0.0042, 95% CI=0.0001-0.089, p<0.0001). Age (HR=7.19, 95% CI=1.08-54.27, p=0.041) and radiological/ clinical progression (HR=3.14, 95% CI=1.35-6.43, p=0.010) were associated with worse overall survival. Intriguingly, radiological/clinical progression was associated with the differential effect of anti-androgen withdrawal on overall survival (interaction p=0.031). Conclusion: Patients who suffer radiological/clinical progression are unsuitable candidates for anti-androgen withdrawal.
AB - Background/Aim: We aimed to identify prognostic and predictive factors for anti-androgen withdrawal syndrome (AWS) to help guide decisions on anti-androgen withdrawal in castration-resistant prostate cancer (CRPC). Patients and Methods: This study included 95 patients with prostate cancer which progressed to CRPC despite primary androgen-deprivation therapy (ADT). AWS was defined as >50% prostate-specific antigen decline after anti-androgen withdrawal. Associations between AWS, and clinicopathological factors and prognosis were investigated. Results: Among the 95 patients, 84 (88.4%) underwent anti-androgen withdrawal, among whom AWS was recognized in nine (10.8%). Gleason score and response duration to primary ADT were predictors of AWS. Long duration of response to primary ADT was also associated with better progression-free survival [hazard ratio (HR)=0.021, 95% confidence interval (CI)=0.0025-0.14, p<0.0001] and overall survival (HR=0.0042, 95% CI=0.0001-0.089, p<0.0001). Age (HR=7.19, 95% CI=1.08-54.27, p=0.041) and radiological/ clinical progression (HR=3.14, 95% CI=1.35-6.43, p=0.010) were associated with worse overall survival. Intriguingly, radiological/clinical progression was associated with the differential effect of anti-androgen withdrawal on overall survival (interaction p=0.031). Conclusion: Patients who suffer radiological/clinical progression are unsuitable candidates for anti-androgen withdrawal.
UR - http://www.scopus.com/inward/record.url?scp=85049807186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049807186&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12702
DO - 10.21873/anticanres.12702
M3 - Article
C2 - 29970538
AN - SCOPUS:85049807186
SN - 0250-7005
VL - 38
SP - 4115
EP - 4121
JO - Anticancer research
JF - Anticancer research
IS - 7
ER -
